The main goal of treatment regimens for metastasis is to control growth rates, not eradicate all cancer cells. Mathematical models offer methodologies that incorporate high-throughput data with dynamic effects on net growth. The ideal approach would simplify, but not over-simplify, a complex problem into meaningful and manageable estimators that predict the response of a patient to specific treatments. We explore here three fundamental approaches with different assumptions concerning resistance mechanisms in which the cells are categorized into either discrete compartments or described by a continuous range of resistance levels. We argue in favor of modeling resistance as a continuum, and demonstrate how integrating cellular growth rates, density-dependent versus exponential growth, and intratumoral heterogeneity improves predictions concerning the resistance heterogeneity of metastases.
The main goal of treatment regimens for metastasis is to control growth rates, not eradicate all cancer cells. Mathematical models offer methodologies that incorporate high-throughput data with dynamic effects on net growth. The ideal approach would simplify, but not over-simplify, a complex problem into meaningful and manageable estimators that predict the response of a patient to specific treatments. We explore here three fundamental approaches with different assumptions concerning resistance mechanisms in which the cells are categorized into either discrete compartments or described by a continuous range of resistance levels. We argue in favor of modeling resistance as a continuum, and demonstrate how integrating cellular growth rates, density-dependent versus exponential growth, and intratumoral heterogeneity improves predictions concerning the resistance heterogeneity of metastases.
Heterogeneity in primary tumors and in metastasis
Within an individual tumor, and between a primary tumor and its metastases, there are particular genotypic or phenotypic variations. Intratumoral heterogeneity implies that different parts of a tumor may have different properties, including the existence of different degrees of sensitivity to various cancer drugs. This heterogeneity has significant implications when developing clinical protocols ( [1, 2] and references therein). Heterogeneity can lead to variations in different fundamental cellular behaviors as a function of time and stress, regardless of the specific mechanisms that may induce it [3, 4] . Changes in these rates of cell division, death, mutation, migration, etc. have direct effects on the dynamic of growth and initiation of metastatic cells. For example, mutations in the Ras-Raf pathway, a type of mitogen-activated protein kinase (MAPK) pathway, may cause increased cell proliferation and resistance to apoptosis [5] . In hepatocellular carcinoma, LMCD1 (LIM and cysteine-rich domains-1) mutations promote cell migration and tumor metastasis [6] .
There are also specific genes that promote genetic stability, including DNA repair genes, DNA damage sensor genes, and cell cycle checkpoint genes. Changes in these stability genes affect the mutation rate [7] . Because these rates are not constant over time, and may vary according to the environment, resistance to chemotherapy becomes a complex dynamic process. Hence, an effective treatment often requires a combination of drugs targeting different resistance mechanisms, based on specific individual genotypic and phenotypic variations.
Along with biological and clinical research, mathematical approaches have been developed to model the development of drug resistance, and have dealt with many of the known aspects of the field [8] . These computational models and their outcomes each have their own definitions of 'resistance' for a given treatment, presented in discrete (e.g., two subgroups of 'sensitive' and 'resistant') or continuous (e.g., a range of values between 0 and 1, where 1 represents the maximum resistance level) ways. In addition to the intrinsic resistance level, there is another factor, the evolution of resistance, which contributes to the dynamics. This factor determines the ability of a cell with a given resistance level to evolve over time and/or space to a different level, based on the processes that were initially assumed. For example, one of these processes is the development of spontaneous or drug-induced mutations.
We discuss here the impact of different assumptions concerning resistance level, resistance evolution, and growth limitation, on the prediction of the dynamics of cancer growth, heterogeneity, and survival. These concepts are described here through the three mathematical models of Stein et al. [9] , Lorz et al. [10] , and Lavi et al. [11] (Box 1). In brief, the Stein model assumes exponential growth for all cells, and includes only the mechanism of intrinsic resistance, with no evolutionary process. In addition, they used a discrete definition of the resistance level that categorized the metastatic cells into two main groups: resistant versus sensitive. Although the Lorz model also assumes exponential growth for all metastatic cells, it also includes resistance evolution with a continuous description of the resistance level. The Lavi model is an extension of the Lorz model, which shares most of the Lorz assumptions, except that exponential growth is replaced with a growth that depends on the cell density. Furthermore, the Lavi model accounts for the occurrence of changes (e.g., epi-mutations) that occur at higher rates than those of genetic mutations.
These realistic assumptions have crucial effects on the predicted level of resistance heterogeneity, and as such integrate differently patient information into more accurate predicted clinical outcomes.
Resistance level as a discrete variable
Although oncologists are aware of the impact of intratumoral heterogeneity, many clinical trials test only one drug. For a given treatment the clinical response and the treatment efficacy are determined by basic measurements, such as the quantification of tumor shrinkage and overall survival (OS), that are not designed to reveal the underlying complexity of the response based on varying resistance levels in different cells in a tumor. Interesting metastatic studies with clinical and practical implications have been reported by Stein and colleagues [9, [12] [13] [14] [15] . These studies offer a method of analyzing tumor response, and predict survival using surrogate and direct measures of tumor volume while a metastasis patient is receiving therapy in a clinical trial. Their main hypothesis is that, for a given treatment, there are two main cell subpopulations, sensitive and resistant. That is, the resistance level can be described by a discrete variable measuring cellular death/ survival. Accordingly, initial tumor shrinkage during treatment is due to a higher portion of sensitive cells in a tumor, and a subsequent increase in the tumor size is a result of the remaining resistant cells that increase in number. The published data [9,12-15] on patients enrolled
Box 1. Mathematical models
Using continuous deterministic models, we describe here the problem of drug resistance by including key mechanisms that control the dynamics of a simplified system of metastasis. Three mathematical models are discussed throughout the paper. Table I in Box 1). r was normalized with the initial tumor size on day 0, in other words, r(0) = 1. They proposed that because the growth rate was found to correlate with OS, it would serve to estimate efficacies of different therapies based on the sampled population or the individual patients. Using these assumptions and method, they concluded that bevacizumab reduces the growth rate constants of renal carcinomas [13] , and that sunitinib reduces the tumor growth rate more than interferon type Ia (IFN-a) [15] . They argued that during treatment, the rate of tumor regrowth (g function in Equation 1 in Table I in Box 1) is a constant value, and for some patients, this indicates that treatment should be continued for a longer period of time because the tumor growth rate is lower than without treatment. The Stein model describes the net growth of the metastatic cells with no information on cellular rates such as cell division or death rates. Sensitive cells are assumed to be cells that did not survive the treatment, regardless of the value of their drug-induced death rate. Note that a treatment producing low rates of drug-induced death and cell division could have the same net growth response as a different treatment with higher rates of drug-induced death and cell division. Therefore, with no further information about cellular growth and death rates, the efficacy of a treatment is only expressed by the net-growth response.
We consider here the approach of Stein et al. with a representative example of partial response (published as part of supplementary Figure S1 , case 12 in [9] ). Their data set serves us throughout this paper as a way to compare three mathematical models, and discuss their assumptions, approaches and the meaning of their results. We estimated the parameters of Equation 1 (see Table III in Box 2) to be d = 0.0541 and g = 0.0005, using a nonlinear least-squares method (for more details see Boxes 1 and 2). The data points and the curve fitted using Equation 1 are plotted in Figure 1A .
Resistance level as a continuous variable The significant variation that has been observed in intratumoral heterogeneity indicates there is a variation in cell division and death rates of cells within a tumor; thus, drug resistance is far from being a black-and-white, resistant or not resistant phenomenon. In view of that, our hypothesis is that a continuous variable is a more appropriate way to describe, estimate, and measure the resistance level. Several direct and indirect interdisciplinary approaches have been suggested to estimate the drug resistance level, depending on the type of data that is analyzed. For instance, clinical data that combine clinical staging, gene expression, and survival data from the same patient can help to categorize a patient as a 'good' or a 'poor' responder in a continuous manner. Such a score can then be used as a more comprehensive method to estimate the different cancer cell phenotypes and their drug sensitivities.
Exponential growth
From a mathematical perspective, Lorz et al. [10] proposed a model for the evolution of cancer cells, r, over time, t (see Equation 2 in Table I in Box 1). Their model is based on an approach previously developed in part by several other groups [16] [17] [18] [19] [20] [21] [22] . It was assumed that the cancer cells had no growth limitations, and grow exponentially. The model was designed to estimate the heterogeneity, n, as a function of the resistance level, x, and time, t. Using this notation, the total number of the cancer cells is described by rðtÞ ¼
Each subpopulation, n(x,t), is based on the rate of cell division, r(x), the spontaneous rate of death, d(x), the rate of drug-induced death, c(x), and the initial condition, IC = n(x,0). All rates are functions of the resistance level. In addition, there are contributions from all other subpopulations, depending only on a genetic mutations function, M(x, y). u(x) denotes the fraction of cells with trait x that can carry out new modifications, where 0 u(x) 1. They suggest that the treatment acts as a selection process, whereas mutations act as a diffusion process.
Once resistance level is included in tumor growth models, we can study how variation in cell division, death, and alteration rates, as a function of the resistance level, can affect the predicted response of the patient. How is such a model different than having a discrete representation of resistance? How can we quantify the dynamic changes in heterogeneity? To address these questions, we analyzed the data points of Stein et al. (squares in Figure 1A ), followed by a simplified version of the Lorz model where we assume exponential growth with no mutations (u = e = 0). We relaxed the assumption that cellular rates are described by step functions, and considered sigmoidal functions instead. The cell division and death rates were estimated using a nonlinear least-squares method (see Table III in Box 2 and Figure 1B) , with an initial condition of 96% of the cancer cell population located below the value of x = 0.5 (IC 1 in Figure 1C and Table III in Box 2) . Heuristically, we are imagining x = 0.5 as the barrier between sensitive and resistant cells. Using the model of Lorz et al., the predicted growth ( Figure 1A) gives information about changes in heterogeneity over time [n(x,t)]. Figure 1C also gives a more detailed description of the 'relapse' case. When starting with approximately 96% 'sensitive' cells (described by IC 1 ), theoretically, after 691 days of treatment, the 'sensitive' cells have not totally been eliminated by the drug (dashed curve) and could affect the net growth over time, after treatment ceases.
We next demonstrate how the net growth ( Figure 2A ) and the heterogeneity ( Figure 2C ) of four different nonzero initial conditions (IC 1 -IC 4 , Figure 2B ) would appear at the end of a treatment (on day 691), using the same rates as in Figure 1 . It is interesting that the growths of both IC 1 and IC 2 are not significantly different, but their heterogeneous compositions include different levels of resistance, The same method was used to estimate the parameters of the growth (g) and the regression (d) rates in the Stein model, with an initial estimate given by the rates found in [9] . The values we obtained for their parameters are d = 0.0541 and g = 0.0005 using in r(t) = e
Àdt + e gt À 1. 
where p 1 = -0.0624, p 2 = 0.0173, p 3 = 0.0846, p 4 = 0.6144.
A sigmoid curve for c(x): 
2D,E 2 All parameters as in the exponential model described above, except for permuted cellular growth rates (j): @nðx; tÞ @t ¼ ½ðr À c À dÞðxÞ þ jðxÞnðx; tÞ
Where jðxÞ $ N 0; 0:25ðr À c À dÞðxÞ ð Þ
All cellular rates and parameters as in Figure 2 It has been previously shown [11] net growth would result in decreasing tumor size. In this case, almost all the initial cells lie in this region.
Variation in cellular rates
One should keep in mind that, the lower the number of sensitive cells, the smaller their contribution within a short time-period. Thus, in the short time-period after a treatment is stopped (t > 691 days), the results derived from the Lorz model do not necessarily contradict the qualitative conclusions of the discrete model. On the other hand, both models are based on a deterministic description, with fixed parameters, and no stochasticity. A noisy environment could result in a more complex resistance distribution, mainly where the cell division and death rates would be closer in value. In this case a clear separation between the two subpopulations would no longer be seen and the conclusions of the two models would be totally different, even for a short period of time.
Variations in cell division and death rates are very common, especially when administering a drug. Using the exponential model (Equation 2, Figure 1A , solid line), we show in Figures 2D ,E the outcome in terms of cancer growth over time and in its heterogeneity on the last day of treatment (t = 691 days), when fixed perturbations of the net growth rate as a function of the trait were included as initial conditions. The net growth rates are sampled from a normal distribution where the mean is the initial 'deterministic growth rate' (which can be estimated from Figure 1B ), and the standard deviation is 25% of that mean. In that specific example, the maximum growth rate among all traits is 0.0721 (absolute value), and the corresponding maximum standard deviation is 0.018. Given the exponential growth (Equation 2), small perturbations of those rates can result in large differences in cell density (3-4 orders of magnitude, see vertical arrow in Figure 2D) , and in the time to reach the minimum tumor reduction (a delay of up to 50 days, horizontal arrow in Figure 2D ). In addition, the heterogeneity at the end of the treatment dramatically varied from the original estimation in the expected traits (x axis) and in the number of cells with those traits (y axis) (colored lines versus black line, Figure 2E ).
Growth with cell density dependence Both models, Stein et al. [9] and Lorz et al. [10] described the total number of metastatic cells, and made an assumption concerning the exponential growth of cancer. However, the total number of cancer cells at any given time can be thought of as an integral of all individual tumors, with different sizes and cell densities: r Total cancer cells ðtÞ ¼ R All tumors r Tumor ðtÞ. These two aforementioned models are thus describing the left-hand side of this equation [i.e., r Total cancer cells (t)]. We can however, consider the more fundamental problem of modeling each tumor individually, and describe the right-hand side of this equation [i.e., R All tumors r Tumor ðtÞ]. Each tumor has its own growth rate, which depends on its heterogeneity and environment. Also, at some point in time, cells may migrate and initiate new tumors with a given probability depending on the type of tumor, the mutations, and the tumor size. Mathematically, this can be modeled, assuming a net growth rate that depends on the intratumoral cell density in addition to the resistance level. The mathematical formula that best describes the 'growth law' of cancer cells has long been debated, though there are three commonly used deterministic functions: exponential, logistic, and Gompertzian [23] [24] [25] [26] [27] [28] [29] . In most computational studies, the early stages of tumors or metastasis may be described as phases of exponential Heterogeneity during treatment, n(x,t)
Key: Key: , where u = 0 and e = 0, using initial condition IC 1 and cellular rates that are described in panel B (see Table III in Box 2). 3 growth, but as the tumor size increases, a slower rate of growth provides a better description. Logistic and Gompertzian laws have been mainly considered for this slower type of growth. Focusing in from a global to a more local tumor level, the rates of cell division and spontaneous death are known to depend on numerous biological parameters, including the local cell density and the resistance level. Cell density relates to various factors that determine tumor growth, such as cell-cell interactions, cell-matrix interactions, the distribution of nutrients, survival signals, the penetration of anticancer drugs, and the pressure within a tumor. In general, many studies have measured the relationship between the cellular rates as functions of cell density in different environmental conditions [1-6,10-12] . In some studies the cell division rate was found to be a decreasing function of cell density [10, 11] , whereas the death rate was described by an increasing function of cell density [1] [2] [3] .
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Opinion
We have extended the approach of Lorz et al. using the same framework to focus on the single tumor level [11] . The cell division and the spontaneous death rates of the cancer cells we assume to depend on the cell density [see functions: f(r), g(r) in Equation 3] . Using the same rates of cell division and death as described above (see Table III in Box 2), we examine the heterogeneity and density over time with the administration of a treatment (t 691 days), for the four initial conditions (IC 1 -IC 4 ) . In all of these cases, the net growth rates decrease to different degrees and the densities are limited ( Figure 3A) . The model is flexible enough to include more information on factors that could limit the tumor size/net growth rate by changing the functions of f(r) and g(r). Accordingly, the n(x,t) for each IC is different than Table III in Box 2). These curves are the solutions of Equation 2 in Table I in Box 1, where u = 0, e = 0 along with the rates in Figure 1B and Table III for exponential growth, even though the same cell division and death rates were assumed ( Figure 3B versus Figure 2C ). For instance, after t = 691 days with treatment, cells with xtrait < 0.1 are still present in this example. Furthermore, this model accounts for the occurrence of genetic as well as non-genetic changes, which occur at higher rates than the genetic mutations. A small mutation rate was already shown to function as a diffusion process for x, because cells with a given trait may spread to a neighboring interval of x values via mutations [10] . Although the effect of such a low rate has a very limited impact on the total cell density, higher rates are expected to increase the spread of x with different cell division and death rates. Therefore, these cells could die or survive depending on their altered traits. We demonstrate the effect of the alteration rate on the tumor density over different scales (Figures 3C,D) . There are two parameters that relate to the alteration process, e and u. The alteration kernel, M(y,x), is considered here to be a Gaussian distribution confined to [0,1] with mean y and variance e 2 /2. In general, the variance, e, is a function of the external stress and time, e(stress, t) (see [11] ). Here, we present a simple case in which these parameters are constant over time. In Figure 3C , we plot the cell densities at the end of the treatment [r(t = 691 days)], while varying the e and u between [0,1]. The upper plot in Figure 3D focuses on lower values of e and u as in [0,0.1]. Both plots clearly demonstrate a decrease in cell density as the alteration rate increases.
Concluding remarks and future perspectives
With the advantages of high-throughput data and new automated techniques comes the obvious problem of how to analyze and understand the high-dimensional complexity of patient information. Researchers can create complex datasets, but a more challenging task is to develop models that are able to simplify and explain complex data. The ideal mathematical approach would simplify, but not over-simplify, complex datasets into meaningful and manageable estimators that predict the response of a patient to specific treatments. Furthermore, there is an urgent need to develop effective methodologies to analyze data from complex diseases such as metastatic cancer, in which tumors are heterogeneous, containing cells with different degrees of drug sensitivity, the source of cancer relapses.
In this paper, we have addressed some of the main aspects relating to the mathematical modeling of drug resistance in metastatic cancer. First, we demonstrated the value of having a model based on a continuous representation of the resistance level. Many primary human tumors have been found to contain genetically distinct cellular subpopulations [1] . Even in a system with a single genetic clone, functional variability has been observed among the tumor cells, with distinct cellular subpopulations and different growth rates [3] . Thus, the definition of 'resistance' should incorporate all possible cases in which tumor cells survive. In addition to the fact that cells could survive the administered treatment, their survival rate should be included in the model. From that perspective, a tumor contains several subpopulations of cancer cells with different net growth rates. The net growth (or survival) rate is a combination of cell division, spontaneous death, and drug-induced death rates. In most, if not all cases there is an additional rate of alteration (e.g., modification, mutation). The better the treatment, the higher the selection, which minimizes heterogeneity due to convergence of the subpopulations with the highest survival rates. However, as was demonstrated here, there may be non-detectable subpopulations that manage to grow at very low survival rates. After a long period of treatment, the global rate of cancer net growth is mainly influenced by the largest subpopulations with the highest survival rates. This is in accord with the discrete resistance model. However, when a second drug is administered to target the selected 'resistant' subpopulations, the undetected cells with different resistance levels appear. Having a method that Table I in Box 1, where u = 0 and e = 0 and the rates in Figure 1B and Table III can predict the underlying dynamic of the heterogeneity might improve the design of treatment protocols for patients that relapse.
The second topic we addressed is the modeling of metastatic cancer cells using a deterministic approach. Metastases are known to spread rapidly, and therefore exponential growth is the commonly used approach in modeling. We demonstrate how small, but likely, variations in the net growth rates may result in a large variation in the predicted tumor size and its heterogeneity over time. Thus, it is difficult to target using specific treatments. This prediction is the outcome of assuming exponential growth.
Our view of metastatic cancer is to some extent different. We suggest modeling metastatic cancer cells as a collection of individual tumors with different growth rates, in which a single cell can be considered as a tumor of minimal size. When tumor size increases, a slower growth rate is observed [30] . We show here how cell density-dependence can change the dynamic of the heterogeneity, mainly by scaling the time to reach the heterogeneity of the exponential model. Thus, the heterogeneity of the exponential model is not necessarily identical to the average of all tumors with density-dependence, which highlights the advantage of using such a model with density-dependence. A full model that includes the probability of initiating new tumors and determines tumor size based on the environment and intratumoral alterations will be the subject of future work.
We would like to emphasize the importance of collecting accurate data for estimating tumor size and its heterogeneity during treatment. This description of tumor heterogeneity should include information on the subpopulations within a tumor, and this should give us a way to quantify rates of cell division, death, alteration, migration, etc. Having such data would dramatically accelerate the development of computational models, and increase their ability to assist in the design of optimal treatment protocols.
